Karen Ansaldo

Statistics

Publications

Citations

134

H-Index

Active since

2017

Affiliations

Translational Genomics Research Institute(Current)

Mayo Clinic in Arizona

HonorHealth

Cancer Research And Biostatistics

University of Arizona

Karen Ansaldo is an author at Translational Genomics Research Institute specializing in pancreatic cancer, chemotherapy, and pancreatic cancer pharmacotherapy.

Publications per year

2017–2019

Publications

Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer

Gayle Jameson, Erkut Borazanci, Hani M. Babiker et al. · JAMA Oncology · 2019 · 74 citations · Full text

Medicine, Oncology, Pharmacology +15

A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer.

Gayle Jameson, Erkut Borazanci, Hani M. Babiker et al. · Journal of Clinical Oncology · 2017 · 23 citations

Medicine, Oncology, Pharmacology +13

A phase II pilot trial of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + cisplatin (C) + gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC).

Erkut Borazanci, Gayle Jameson, Mitesh J. Borad et al. · Journal of Clinical Oncology · 2018 · 21 citations

Medicine, Oncology, Pharmacology +17

A phase II pilot trial of nivolumab + albumin bound paclitaxel + paricalcitol + cisplatin + gemcitabine (NAPPCG) in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma.

Erkut Borazanci, Gayle Jameson, Mitesh J. Borad et al. · Journal of Clinical Oncology · 2017 · 16 citations

Medicine, Oncology, Pharmacology +17

1–4 of 4